Hurley Capital’s Abivax ABVX Stock Holding History

Hurley Capital’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,015	Closed	-$23.1K	–	690
2025 Q2	$23.1K	Hold	3,015	–	–	0.02%	216
2025 Q1	$18.8K	Buy	+3,015	New	+$20.4K	0.01%	263

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Hurley Capital's ABVX Position: Q3 2025 in Review

Hurley Capital sold out of Abivax (ABVX) in Q3 2025, closing a stake of 3,015 shares — an estimated $23.1K sold.

Hurley Capital first reported a position in ABVX in Q1 2025 and held it in 2 quarters. The position peaked at $23.1K in Q2 2025. 165 funds tracked by Wall St. Rank hold ABVX as of Q3 2025.

Hurley Capital reported no remaining Abivax position as of Q3 2025 after selling out during the quarter.
Hurley Capital sold 3,015 Abivax shares in Q3 2025, an estimated $23.1K.
Hurley Capital first reported a position in Abivax in Q1 2025 and held it in 2 quarters.
Hurley Capital's Abivax position peaked at $23.1K in Q2 2025.
165 funds tracked by Wall St. Rank held Abivax as of Q3 2025.

Based on Hurley Capital's 13F filing for Q3 2025, filed 12 Nov 2025.